Clinical Trial Update: Botox for Neurogenic Detrusor Overactivity and the Prevention of Autonomic Dysreflexia Following SCI [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update investigating Botox for neurogenic detrusor overactivity and prevention of autonomic dysreflexia after spinal cord injury has comp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autonomic Dysreflexia
• Neurogenic Detrusor Overactivity
• Spinal Cord Injury

Drugs mentioned

• Botox (OnabotulinumtoxinA)

Snippet

Sponsor: Rick Hansen Institute | Conditions: Autonomic Dysreflexia | Phase 4 | Status: COMPLETED